Results 101 to 110 of about 21,895 (224)

Pemphigoid: Bullous and Cicatricial

Dermatologic Clinics, 1990
Bullous pemphigoid is a blistering disease of the elderly that often is self-limited. It is apparently caused by autoantibodies against antigens of the basal cell hemidesmosome. There is apparently more than one antigen, but the most significant has a molecular weight of about 230 kD and the second most frequently detected antigen has a lower molecular
openaire   +2 more sources

Successful Treatment of Severe Adult Linear IgA Dermatosis Using Dupilumab

JEADV Clinical Practice, Volume 5, Issue 3, Page 943-945, September 2026.
ABSTRACT Linear IgA dermatosis (LAD) is a rare autoimmune subepidermal bullous dermatosis, characterised by the presence of erythematous vesiculobullous lesions arranged in rosettes or herpetiform clusters. The standard treatment involves the administration of dapsone, followed by sulfasalazine, and general corticosteroid therapy, often in combination ...
Célia Delesalle, Claire Abasq‐Thomas, Claire Bocciarelli, Amélie Bourhis, Marina Alexandre, Belen Eguia, Laurent Misery, Numa Deydier   +7 more
wiley   +1 more source

The association between COVID‐19 vaccines and bullous pemphigoid risk: A UK population‐based study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Mikolaj Swiderski, Yana Vinogradova, Matthew J. Ridd, Zenas Z. N. Yiu, Antonia Lloyd‐Lavery, Vibhore Prasad, Bruno Gran, Sonia Gran   +7 more
wiley   +1 more source

Abscopal Effect in Radiation Therapy: The Immune Mechanisms and Clinical Advances

MedComm, Volume 7, Issue 9, September 2026.
The schematic outlines the key events of the abscopal effect. (Ignition) Local radiotherapy (RT) induces the release of immunogenic signals from the tumor, leading to dendritic cell (DC) activation. (Orchestration) In the tumor‐draining lymph node (TDLN), DCs prime naive T cells into cytotoxic T lymphocytes (CTLs), a process modulated by regulatory T ...
Yihong Dong, Moran Chen, Xupeng Hou, Xiaoya Tang, Xiaoli Yu, Jing Liu   +5 more
wiley   +1 more source

Bullous Pemphigoid [PDF]

JAMA Dermatology, 2013
Misha, Rosenbach, Karolyn A, Wanat, Cassio, Lynm   +2 more
openaire   +2 more sources

Dupilumab as a treatment for bullous pemphigoid in a liver transplant recipient: A case report

SAGE Open Medical Case Reports
Bullous pemphigoid is a common subepidermal autoimmune bullous disease that affects the skin and mucous membranes. It is more prevalent in the elderly, often resulting in significant morbidity and mortality.
Sarah S. Rashid, P. Régine Mydlarski, Fatemeh Jafarian   +2 more
doaj   +1 more source

Bullous Pemphigoid [PDF]

Journal of General Internal Medicine, 2012
Barry, Ladizinski, Kachiu Cecelia, Lee
openaire   +2 more sources

Complement-Activating Capacity of Autoantibodies Correlates With Disease Activity in Bullous Pemphigoid Patients

Frontiers in Immunology, 2018
Background: Bullous pemphigoid is a subepidermal blistering skin disease, associated with autoantibodies to hemidesmosomal proteins, complement activation at the dermal-epidermal junction, and dermal granulocyte infiltration.
Roxana M. Chiorean, Roxana M. Chiorean, Adrian Baican, Mayson B. Mustafa, Annette Lischka, Daniel-Corneliu Leucuta, Vasile Feldrihan, Michael Hertl, Cassian Sitaru, Cassian Sitaru   +9 more
doaj   +1 more source

Type‐2‐Inflammatory‐Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

Allergy, Volume 81, Issue 9, Page 3345-3360, September 2026.
Studies suggest that type 2 inflammatory diseases are driven by overactivation of the IL4/IL13 pathway, manifesting differently in distinct tissues. We performed quantitative analyses using several large independent datasets to explore the interrelation of type 2 inflammatory diseases based on co‐prevalence, genetic predispositions, and transcriptomic ...
Jennifer D. Hamilton, Manuel A. R. Ferreira, Wei Keat Lim, Carlo Sidore, Matthew F. Wipperman, Wenzhen Ge, Xue Song, Changming Xia, Julie E. Horowitz, Andrea T. Hooper, Sara C. Hamon, Jennifer Maloney, Jamie M. Orengo, Zhen Chen, Stephanie Amato Ricci, Bolanle Akinlade, Aris Baras, Gary Herman, Brandy L. Bennett, George D. Yancopoulos   +19 more
wiley   +1 more source

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor in primary care: Case report

Turkish Journal of Family Practice
Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies suggest dipeptidyl peptidase-4 inhibitors used in the treatment of type-2 diabetes as possible predisposing agents of bullous pemphigoid.
Kübra Kurt
doaj   +1 more source